Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Af-001 in Differentiated Thyroid Cancer
NCT07287748Phase 1Recruiting
- Sponsor
- Alpha Fusion, Inc.
- Start
- Jan 2026
- Primary completion
- Jul 2028
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sodium astatide (211At) in differentiated thyroid cancer (DTC) (3 arms), sponsored by Alpha Fusion, Inc. Primary endpoints: Dose-limiting toxicity at 4 weeks and Assessment of tumor reduction effect at 24 weeks. Started Jan 2026; status: recruiting.
02
Drugs
sodium astatide (211At)
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT07287748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07287748.